Introduction
============

Obsessive-compulsive disorder (OCD) and chronic tic disorders (CTDs) can be highly impairing conditions which affect a wide range of youth. Multiple prevalence estimates for children and adolescents indicate that approximately 1%--2% of children experience OCD, 0.5%--1.0% experience Tourette Disorder, 1.0%--2.0% experience chronic tic disorders and approximately 5% experience transient tic disorders.[@b1-jcnsd-3-2011-125]--[@b7-jcnsd-3-2011-125] Obsessive-compulsive disorder is characterized by unwanted intrusive cognitions that persist against the patient's wishes (obsessions) followed by repetitive behaviors intended to reduce associated distress (compulsions), which can be variably expressed.[@b8-jcnsd-3-2011-125]--[@b10-jcnsd-3-2011-125] The content of obsessions often includes perceived contamination, uncertainty about completing an action (eg, checking locks), taboo thoughts (ie, sexual, religious, aggressive), and symmetry and ordering obsessions. Common compulsions include excessive hand washing, repetitive touching of objects, covert rituals (eg, counting, praying), reassurance seeking, unnecessary checking to ensure tasks have been completed, and ordering of objects in a certain configuration until they are perceived as "in order". Tic disorders are characterized by both simple and complex tics, which are often manifest themselves through motor actions (eg, eye-blinking, shoulder shrugging, or detailed facial gestures) and verbal expressions (eg, groaning, cursing in public despite no intention of doing so). Tic disorders encompass chronic tic disorder (CTD), transient tic disorder (TTD), and Tourette Disorder (TD); CTDs (motor or verbal) are often grouped with TD in treatment trials and in conceptualization of pathology, whereas transient tic disorder has received less focus in clinical research. Thus, this review will address CTD and TD under the umbrella of CTDs. Obsessive-compulsive disorder and CTDs share similarities in phenotypes and neurobiology and are commonly comorbid: a modest amount of children with a principal diagnosis of OCD experience comorbid tics (20%--40%), while a higher percentage of youth with tics experience comorbid OCD (20%--60%).[@b11-jcnsd-3-2011-125]--[@b17-jcnsd-3-2011-125] Comorbid tics are more frequent in younger OCD patients, and both disorder classes are more prevalent in younger boys.[@b18-jcnsd-3-2011-125]

Obsessive-compulsive disorder and CTDs interfere with the child's functioning in the school, interpersonal, emotional, and home domains.[@b19-jcnsd-3-2011-125]--[@b28-jcnsd-3-2011-125] In clinical samples, over half of patients with both conditions have been observed to experience functional difficulty due to symptoms of both conditions,[@b21-jcnsd-3-2011-125],[@b24-jcnsd-3-2011-125] with many patients having two or more problem areas in functioning. This is particularly problematic given that these conditions can occur during critical periods of social and academic development for youth, where interference from these conditions can lead to missing out on critical experiences which may affect optimal functioning in adulthood (eg, reduced access to social and academic opportunities can lead to difficulty in vocational and social functioning as adults due reduced experiences of age appropriate norms). For example, a child with OCD may have compulsions getting in the way of completing school assignments, or a child with vocal tics may have difficulty practicing reading aloud before the class or speaking to the teacher, and children with both conditions may experience distraction due to obsessions or premonitory urges that can interfere with concentration inside and outside of the classroom.

Neurobiological research of OCD has focused on the orbitofrontal cortex (along with the amygdala) in a fear learning model. Although its etiology is multidetermined, OCD has a genetic component, with increased risk of familial transmissionand some observed genetic loci of interest that merit further investigation.[@b29-jcnsd-3-2011-125]--[@b36-jcnsd-3-2011-125] Additionally, alterations in glutamatergic functioning may also be associated with OCD.[@b37-jcnsd-3-2011-125] Other research foci in the development of OCD haveimplicated fear learning,[@b38-jcnsd-3-2011-125] operant theory,[@b39-jcnsd-3-2011-125] cognitive theory,[@b40-jcnsd-3-2011-125] and sensitivity to negative affect.[@b41-jcnsd-3-2011-125]

Tic disorders are associated with dysfunction of the prefrontal cortex and the basal ganglia along with the limbic system.[@b42-jcnsd-3-2011-125],[@b43-jcnsd-3-2011-125] Androgens have been implicated in the childhood development of OCD and CTDs, with empirical support provided by the elevated morbidity rate of both conditions in early youth as well as the study of androgen roles in CTDs. Tic disorders also have a genetic basis, with increased risk observed in family members of probands who experience tics.[@b44-jcnsd-3-2011-125],[@b45-jcnsd-3-2011-125] Research on genetic inheritance for both conditions indicate polygenetic influences with some overlap.[@b46-jcnsd-3-2011-125] Environmental risks for OCD/CTDs have also been identified such as perinatal difficulties,[@b47-jcnsd-3-2011-125] traumatic experiences,[@b48-jcnsd-3-2011-125],[@b49-jcnsd-3-2011-125] and immune related risks.[@b7-jcnsd-3-2011-125],[@b50-jcnsd-3-2011-125]--[@b54-jcnsd-3-2011-125]

A variety of orally administered pharmacotherapies have demonstrated efficacy for youth with OCD and CTDs, each with specific benefits and risks. The purpose of this review is to delineate medication options based on clinical research, with randomized clinical trial (RCT) evidence being weighted most highly followed by open trial evidence, with case reports and other uncontrolled research holding less influence. Controlled evidence is particularly pertinent for tic disorders, as tic severity may fluctuate over relatively brief periods of time.[@b55-jcnsd-3-2011-125]--[@b57-jcnsd-3-2011-125] An appropriate control group is necessary to separate medication effect from a naturalistic course. Emphasis is placed on the efficacy, safety, tolerability, and relative place in evidence based support of these agents. Empirical work was included if the predominant focus of the research was on children; exceptions were made only in the case of lack of pediatric research for a particular agent, and such research with an adult focus has been specifically identified. While there is little evidence to indicate that OCD and CTDs present with substantial differences between children and adults that affect treatment decision making, the evidence base for pharmacotherapy is more robust for adults. The majority of medications indicated for children have also been shown efficacious with adults, and any substantial discrepancies are explicitly noted. Psychopharmacological research for OCD and CTDs is first addressed separately for each respective condition, with subsequent focus on issues in the clinical management of each condition both individually as well as in the context of comorbidity. While cognitive behavioral therapy (CBT) has also been established as efficacious for pediatric OCD and habit reversal training has strong support for treating childhood CTDs,[@b58-jcnsd-3-2011-125],[@b59-jcnsd-3-2011-125] the focus of this review is on pharmacotherapy, and behavioral therapies are discussed only in the context of available treatment options in deciding on medication selection.

Pharmacotherapy Options for the Treatment of Pediatric OCD
==========================================================

Selective reuptake inhibitor (SRI) medications have received the majority of research with pediatric OCD, which encompass the selective serotonin reuptake inhibitors (SSRIs) and a specific tricyclic antidepressant (clomipramine), and over 1,000 patients are now available for comparison in meta-analysis. Meta- analysis of RCTs have indicated that these medications have a significant effect relative to placebo, with overall effect size estimates ranging from 0.46--0.48, and with clomipramine showing a significant advantage over SSRIs in efficacy relative to placebo.[@b60-jcnsd-3-2011-125],[@b61-jcnsd-3-2011-125] However, head to head comparisons between clomipramine and SSRIs in a single trial are unavailable, and variables in study design and subject selection can influence effect sizes. Additionally, other factors (such as tolerability) have implications for treatment selection.

Evidence for the use of SRIs in pediatric OCD has been most conclusively demonstrated through RCTs,[@b62-jcnsd-3-2011-125]--[@b72-jcnsd-3-2011-125] which have demonstrated efficacy for clomipramine, sertraline, fluoxetine, fluvoxamine and paroxetine (with pooled RCT effect sizes for each medication observed to be 0.85, 0.47, 0.51, 0.31, and 0.44, respectively).[@b61-jcnsd-3-2011-125] With regard to prescriptive use for children, the United States Food and Drug Administration (FDA) has provided approval for pediatric OCD treatment for clomipramine (ages 10 and above), sertraline (ages 6 and above), fluoxetine (ages 7 and above), and fluvoxamine (ages 8 and above). For each of these medications, dosing titration using the lowest recommended dose with incremental increases every 2--4 weeks based on efficacy and tolerability is recommended. Frequent visits at treatment initiation are also recommended, followed by less frequent monitoring after the medication regimen is stabilized.[@b73-jcnsd-3-2011-125]

Selective Serotonin Reuptake Inhibitors (SSRIs)
===============================================

Among FDA approved SSRIs for pediatric OCD, no significant efficacy differences have been observed,[@b60-jcnsd-3-2011-125],[@b61-jcnsd-3-2011-125] and no direct comparisons have been made in the context of a single trial. Thus, choice of agent usage is relegated to preferred half-life, observed patient response, and idiographic tolerability of an individual agent, as the SSRIs do differ from one another in pharmacodynamics and drug interactions. In pediatric OCD trials, more commonly reported side effects of SSRIs include abdominal discomfort, decreased appetite, sleep interference in the form of either insomnia or somnolence, and fatigue.[@b67-jcnsd-3-2011-125],[@b68-jcnsd-3-2011-125],[@b74-jcnsd-3-2011-125],[@b75-jcnsd-3-2011-125] While these side effects are not commonly prohibitive, significant patient dropout (22%) attributable to side effects has been observed in pediatric OCD trials.[@b61-jcnsd-3-2011-125] The FDA Black Box warning for suicidality for SSRIs has addressed concern regarding the administration of SSRI medications,[@b76-jcnsd-3-2011-125],[@b77-jcnsd-3-2011-125] which was based on a compilation analysis of data from RCTs in children with depression and anxiety disorders as well as on lay testimony of perceived risks. The risk for suicidal behaviors are theorized to occur in the context of behavioral activation,[@b78-jcnsd-3-2011-125] a phenomenon which can involve agitation, hostility, restlessness, impulsivity, emotional lability, and insomnia. These symptoms are most often seen 1--9 days after a dose change,[@b78-jcnsd-3-2011-125],[@b79-jcnsd-3-2011-125] where younger children may be at higher risk from activation syndrome (with particular focus placed on mood and irritability).[@b77-jcnsd-3-2011-125],[@b80-jcnsd-3-2011-125] When considering SSRI suicide risk by diagnosis, Bridge et al found no statistically significant increase in risk of suicidal thinking or behavior when considering pediatric OCD SSRI trials,[@b81-jcnsd-3-2011-125] where they found an increased risk difference between SSRIs and placebo to be 0.5 and a number needed to harm of 200. Nevertheless, while such risk may have been higher in trials for depression relative to those for OCD,[@b81-jcnsd-3-2011-125] providers must carefully monitor for increased suicidal ideation when administering SSRIs to children with OCD, especially considering the high comorbidity rate with depression,[@b82-jcnsd-3-2011-125]--[@b84-jcnsd-3-2011-125] which sometimes may go undetected given the difficulties in diagnosing pediatric internalizing disorders. [@b85-jcnsd-3-2011-125] Managing activation can be accomplished by titrating and adjusting doses slowly, using the minimum therapeutic dose, and/or changing to a different medication.[@b75-jcnsd-3-2011-125] Additionally, practice parameters recommend the use of CBT alone in mild and moderate severity cases, and together with a SSRI in more severe cases.[@b72-jcnsd-3-2011-125] The combination approach should be considered given its efficacy and tolerability with the additional benefit of reduced suicidal symptoms reported in those receiving CBT + SSRI versus those receiving only SSRI treatment.[@b86-jcnsd-3-2011-125]

Clomipramine
============

Clomipramine was the first antidepressant to demonstrate efficacy in RCTs for pediatric OCD and is FDA approved in treating youth with OCD ages 10 and older.[@b67-jcnsd-3-2011-125],[@b68-jcnsd-3-2011-125],[@b71-jcnsd-3-2011-125] It has demonstrated relatively stronger effects in reducing obsessive-compulsive symptoms than the SSRIs, with an estimated effect size of 0.85 relative to placebo.[@b61-jcnsd-3-2011-125] Clomipramine is a tricyclic antidepressant which exerts effects on serotonin and norepinephrine, which may partially account for its increased efficacy relative to the selective agents.[@b60-jcnsd-3-2011-125] When using clomipramine, a baseline electrocardiogram (EKG) is indicated to observe for cardiac arrhythmia, and further EKG monitoring along with blood level monitoring of medication levels is indicated. Other side effects associated with clomipramine include dry mouth, somnolence, dizziness, fatigue, tremor, weight gain, and constipation.[@b67-jcnsd-3-2011-125],[@b68-jcnsd-3-2011-125] Thus, while clomipramine has the strongest demonstrated efficacy among medications for pediatric OCD, it is often not indicated as a first-line agent due to its side effects, with particular concern given to its relationship with cardiac arrhythmia.[@b60-jcnsd-3-2011-125],[@b87-jcnsd-3-2011-125],[@b88-jcnsd-3-2011-125]

Other Agents
============

Atypical antipsychotics have drawn the majority of attention among other agents in treatment for OCD, with particular attention given to their role in augmenting non- or partial-response to SRIs. Some data support this practice among adults; one recent meta-analysis suggests such use to be considered after 12 weeks of incomplete response to two adequate trials of SRI therapy.[@b89-jcnsd-3-2011-125] However, despite its frequent use in youth, no methodologically rigorous data exist regarding antipsychotic augmentation of SRI therapy in youth with OCD beyond case reports.[@b90-jcnsd-3-2011-125],[@b91-jcnsd-3-2011-125] Additionally, there are concerning metabolic and cardiac effects associated with antipsychotic use among youth.[@b92-jcnsd-3-2011-125] Given the lack of RCT data and the risks of associated adverse effects, this option should only be considered after failure of appropriate CBT (of sufficient duration by a professional with expertise) and when symptoms are severely impairing functioning. Further evidence beyond uncontrolled reports is required to justify its use in youngsters with OCD.[@b93-jcnsd-3-2011-125]

A new direction in augmenting agents involves the glutamate modulators memantine and riluzole, which have had open trial support for treatment resistant OCD in youth,[@b94-jcnsd-3-2011-125]--[@b96-jcnsd-3-2011-125] with promising results. While preliminary, these medications provide an alternative to the traditional serotonin hypothesis in pharmacotherapy for pediatric OCD. Other glutamate modulators such as n-acetylcysteine and glycine have been theorized to be of pharmaceutical use, but no evidence currently exists to support their efficacy in pediatric OCD.[@b97-jcnsd-3-2011-125]

Pharmacotherapy Options for the Treatment of Pediatric Chronic Tic Disorders
============================================================================

The two major classes of medication that have been indicated as efficacious with pediatric chronic tic disorders are dopamine antagonists (typical and atypical), and alpha-2 agonists. While no meta-analytic estimates exist with regard to the efficacy of these agents, the effect sizes of antipsychotics relative to placebo are larger than those for alpha-2 agonists.[@b98-jcnsd-3-2011-125]--[@b103-jcnsd-3-2011-125] Given the unique pharmacodynamic and pharmacokinetic characteristics of these medications, treatment choice is guided by weighing risks of adverse effect profile versus expectancy of treatment response.

Typical Antipsychotics
======================

Typical antipsychotics were the first medications to display efficacy in controlled research for pediatric tic disorders, and thus have the broadest evidence base. The only medication with FDA approval for pediatric CTDs is pimozide (ages 12 and older). Haloperidol has a long history in the treatment of CTDs, with evidence stretching back 50 years.[@b104-jcnsd-3-2011-125] While RCTs have demonstrated the efficacy of haloperidol in adults,[@b105-jcnsd-3-2011-125] controlled evidence in youth is lacking; one crossover trial failed to find efficacy relative to placebo on the primary outcome measure,[@b106-jcnsd-3-2011-125] though secondary outcome measures of global functioning detected overall improvement. Side effects that are frequently reported include extrapyramidal symptoms, sedation/drowsiness, weight gain, and increased prolactin secretion. Dosage reduction can be used to manage these side effects. Side effects from typical antipsychotics that can be serious include tardive dyskinesia and neuroleptic malignant syndrome. For CTDs, much lower doses are used than those used for psychotic disorders. For this reason and perhaps because of neurobiological differences, those with CTDs appear to have low risk for tardive dyskinesia. Estimates of the risk of tardive dyskinesia in children and adolescents treated for TD range from 1%--4.8%.[@b107-jcnsd-3-2011-125]--[@b110-jcnsd-3-2011-125] However, the risk of such effects increases with greater treatment duration and dosage, may persist after treatment discontinuation.[@b111-jcnsd-3-2011-125],[@b112-jcnsd-3-2011-125]

Pimozide, which is a less powerful antagonist of norepinephrine than haloperidol, has been employed in treatment for pediatric CTDs. Its efficacy has been established in RCTs,[@b106-jcnsd-3-2011-125],[@b113-jcnsd-3-2011-125] with fewer adverse effects than haloperidol. However, it still presents with a substantial side effect profile including weight gain, akathisia, acute dystonia, QTc prolongation, tardive dyskinesia, and extrapyramidal effects.[@b114-jcnsd-3-2011-125] Given its QTc effects, electrocardiograms at baseline, during titration, and at regular intervals throughout treatment are indicated. Additionally, interactions with antidepressant medications (which are commonly employed with OCD, such as fluvoxamine) have been observed, which presents substantial concern when working with comorbid conditions.

Fluphenazine, which has antagonistic properties for both D1 and D2 receptors, is better tolerated than haloperidol with regard to sedation and extrapyramidal effects while showing similar efficacy to haloperidol in adults.[@b115-jcnsd-3-2011-125],[@b116-jcnsd-3-2011-125] However, controlled data in youth are lacking. Despite its relatively more desirable side effect profile, fluphenazine still presents the risks of traditional neuroleptic adverse effects including akathisia, tardive dyskinesia, and extrapyramidal effects.

Atypical Antipsychotics (Second Generation Antipsychotics)
==========================================================

The more recently introduced atypical antipsychotics have now garnered a substantial evidence base with regard to efficacy for pediatric CTDs. The major advantage of atypical antipsychotics is the reduced risk of tardive dyskinesia and extrapyramidal symptoms associated with classic neuroleptics. However, there are concerns about the safety and tolerability of these medications, especially with regard to increased levels of prolactin (with the exceptions of aripiprazole, quetiapine, and clozapine), sedation, and metabolic effects which can lead to elevated glucose levels, increased appetite, and weight gain.[@b117-jcnsd-3-2011-125]

The medication with the most research evidence in treatment for CTDs is risperidone, with efficacy demonstrated through four RCTs (effect sizes = 0.55--1.0).[@b98-jcnsd-3-2011-125],[@b118-jcnsd-3-2011-125]--[@b120-jcnsd-3-2011-125] However, risperidone has been associated with weight gain, increased prolactin levels, and sedation/fatigue as common side effects.[@b121-jcnsd-3-2011-125] Nevertheless, the tolerability of risperidone has been considered preferable to that of traditional neuroleptics such as haloperidol.[@b103-jcnsd-3-2011-125]

Ziprasidone has 5HT-2 and D2 antagonistic properties along with norepinephrine and 5HT reuptake inhibition. It has RCT evidence to demonstrate efficacy relative to placebo (effect size = 0.76),[@b100-jcnsd-3-2011-125] but merits EKG monitoring due to effects on QTc.[@b92-jcnsd-3-2011-125],[@b122-jcnsd-3-2011-125],[@b123-jcnsd-3-2011-125] Additionally, mild sedation has been observed.[@b100-jcnsd-3-2011-125] Thus, while it has been demonstrated as efficacious, particular concern with regard to its effect on cardiac conduction raises caution when considering its use. Additionally, while mild sedation has been observed.[@b100-jcnsd-3-2011-125] It is perhaps the atypical antipsychotic with the lowest weight gain profile.

Olanzapine has displayed efficacy in children with CTDs in several open trials[@b124-jcnsd-3-2011-125]--[@b126-jcnsd-3-2011-125] and one small crossover trial.[@b127-jcnsd-3-2011-125] However, it has increased risk from weight gain and metabolic effects relative to other atypical antipsychotics.[@b121-jcnsd-3-2011-125],[@b124-jcnsd-3-2011-125],[@b128-jcnsd-3-2011-125] Thus, given its other associated side effects such as sedation and increased prolactin levels, consideration for its use in CTDs should be made in the context of other available medicinal and behavioral treatment options.

Aripiprazole is a D2 regulator (partial agonist/antagonist), addressing hyperdopaminergic conditons in the limbic system and hypodopaminergic condition in the frontal and prefrontal cortices.[@b129-jcnsd-3-2011-125] Multiple open trials have indicated improvement in CTD symptoms,[@b130-jcnsd-3-2011-125]--[@b133-jcnsd-3-2011-125] but controlled evidence in children is currently lacking, although RCTs are underway. Sedation, nausea, headache, agitation, and insomnia have been observed as side effects; some weight gain has been observed, but to a lesser degree than other comparable agents.[@b121-jcnsd-3-2011-125],[@b134-jcnsd-3-2011-125]

Quetiapine has empirical support from one open label trial,[@b135-jcnsd-3-2011-125] but lacks RCT evidence to support its use. It is a weaker D2 antagonist than comparable medications, and thus its theoretical efficacy for CTDs is questioned. Abdominal discomfort, gastrointestinal upset, somnolence, and weight gain have been observed as common side effects.

Given the observed side effects of atypical antipsychotics, careful observation of adverse effects is recommended. With regard to metabolic effects, the American Diabetes Association has published monitoring guidelines for these agents.[@b136-jcnsd-3-2011-125] While these criteria have not been empirically validated, they provide a starting point in evaluating metabolic side effects with patients. Correll[@b92-jcnsd-3-2011-125] has recommended detailed monitoring schedules that include testing for glucose, lipids, and liver function at three months after treatment initiation and then every six months thereafter, and to evaluate for sedation and weight gain at each visit. Additionally, symptoms of elevated prolactin can include menstrual interruption in females and breast tenderness in males and females, and merit further inquiry upon observation. Proactive management of such effects is recommended including adjusting dosing, changing medications, and monitoring of lifestyle habits (eg, appropriate diet and exercise).

Alpha-2 Agonists
================

The alpha-2 agonists clonidine and guanfacine have demonstrated efficacy in treating pediatric CTDs. While observed effect sizes in treating CTDs have been lower than those for antipsychotics, the major benefits of the alpha-2 agonists relative to antipsychotics is their reduced side effect profile (which does not include metabolic interference or extrapyramidal symptoms) and their efficacy for comorbid ADHD.[@b137-jcnsd-3-2011-125]

Clonidine has demonstrated efficacy in RCTs for CTDs (effect sizes = 0.26--0.57),[@b101-jcnsd-3-2011-125],[@b118-jcnsd-3-2011-125],[@b138-jcnsd-3-2011-125] with fewer side effects than neuroleptic and atypical antipsychotic medication. Common side effects reported with clonidine use include sedation, irritability, headaches, and dry mouth. However, given its short half-life, withdrawal symptoms such as temporary increases in blood pressure and heart rate have been reported.[@b139-jcnsd-3-2011-125],[@b140-jcnsd-3-2011-125] Thus, blood pressure and pulse should be monitored at baseline and during titration, with some recommendations for baseline and follow up ECGs.[@b141-jcnsd-3-2011-125]

Guanfacine is more highly selective for the alpha- 2-adrenergic receptors, which is hypothesized to be the reason for its improved side effect profile relative to clonidine (with particular regard to sedation). It also has a longer half-life than clonidine, reducing the risk of withdrawal effects and permitting for more convenient dosing (which can be limited to twice per day). Efficacy of treatment for CTDs has been demonstrated for guanfacine through RCTs (effect sizes = 0.67--0.84), with one including comorbid ADHD.[@b102-jcnsd-3-2011-125] Although one study did not detect improvement over placebo,[@b142-jcnsd-3-2011-125] it was limited by a small sample size, short duration, and a floor effect due to mild baseline tic severity.

Other Agents
============

The efficacy of the anticonvulsant topiramate was recently supported through an RCT by Jankovic et al. (ES = 1.01),[@b99-jcnsd-3-2011-125] and has further support from retrospective chart reviews.[@b143-jcnsd-3-2011-125] Like the alpha-2 agonists, topiramate has the advantage of no risk of extrapyramidal side effects or weight gain relative to typical or atypical antipsychotics. Common observed side effects include somnolence, weight loss, and cognitive slowing. The anticonvulsant levetiracetam has shown open-label evidence for improving tics;[@b144-jcnsd-3-2011-125],[@b145-jcnsd-3-2011-125] however, two small randomized crossover trials did not detect a tic-reducing effect.[@b101-jcnsd-3-2011-125],[@b146-jcnsd-3-2011-125] Commonly reported side effects include somnolence, headache, dizziness, and asthenia. Significant agitation has also been associated with levetiracetam use and suicidal ideation has been observed in 1% of patients,[@b147-jcnsd-3-2011-125],[@b148-jcnsd-3-2011-125] which merits close monitoring for psychiatric adverse events during administration.[@b149-jcnsd-3-2011-125]

Mecamylamine is a nicotine receptor agonist which has conflicting research support, where a retrospective case report series indicated some efficacy,[@b150-jcnsd-3-2011-125] but it did not demonstrate superiority to placebo in a well-designed RCT.[@b151-jcnsd-3-2011-125] Nicotine (via gum or transdermal patch) as an augmentation strategy with haloperidol has been investigated, with open trial evidence showing minor effects for CTDs,[@b152-jcnsd-3-2011-125] but an RCT did not support its efficacy.[@b151-jcnsd-3-2011-125] Baclofen is an agent that interacts with GABA to inhibit the release of various neurotransmitters (including glutamate), which has support in a large open label trial,[@b153-jcnsd-3-2011-125] and a small RCT indicated significant difference from placebo on the CGI--Severity,[@b154-jcnsd-3-2011-125] but only near-significance on the Yale Global Tic Severity Scale (YGTSS).[@b155-jcnsd-3-2011-125],[@b156-jcnsd-3-2011-125] For very localized tics, botulinum toxin has been studied, with some evidence from open trials.[@b157-jcnsd-3-2011-125],[@b158-jcnsd-3-2011-125] In an RCT, botulinum toxin reduced number of tics per minute as recorded on videotape, but patients did not report perceived benefit.[@b159-jcnsd-3-2011-125] Additionally, although botulinum toxin may display some effectiveness in addressing a very localized tic (eg, facial grimacing), it does not address the underlying psychopathology as tics may simply be reassigned to different body parts,[@b159-jcnsd-3-2011-125] and thus it should not be considered a common treatment for a wide variety of tics.

Other agents that interact with the dopaminergic system include metoclopramide, tetrabenazene, tiapride, sulpriride, and pergolide. Metaclopromide is a D2 antagonist which has traditionally been used for gastroesophageal reflux disease and as an anti-nausea agent, with side effects that can include sedation, increased appetite, and increased levels of prolactin, along with a risk of tardive dyskinesia and extrapyramidal symptoms.[@b160-jcnsd-3-2011-125] Though it has a limited evidence base for CTDs, in a small RCT it demonstrated efficacy compared to placebo (effect size = 0.95).[@b161-jcnsd-3-2011-125] Tetrabenazine is a dopamine agonist that intercedes in dopamine reuptake, which has case series and open trial support.[@b162-jcnsd-3-2011-125]--[@b164-jcnsd-3-2011-125] Side effects include sedation, depression, nausea, insomnia, akathisia, and parkinsonism, and insomnia. Tiapride is a benzamide that has some support through an RCT to improve tics compared to placebo,[@b165-jcnsd-3-2011-125] with hyperprolactinemia, somnolence, and weight gain as side effects of note. Sulpiride is similar to tiapride, and has some support through retrospective studies to improve tics in adults.[@b166-jcnsd-3-2011-125] The most common side effects reported were sedation and depression, although tardive dyskinesia was reported in a case report.[@b167-jcnsd-3-2011-125] Both sulpiride and tiapride are available in Europe but not in the United States. Pergolide interferes with dopamine release and has been investigated for use in Parkinson's disease. While efficacy compared to placebo has been reported,[@b168-jcnsd-3-2011-125],[@b169-jcnsd-3-2011-125] pergolide has been associated with cardiac valve pathology in treatment for Parkinson's disease and has been withdrawn from the United States market.[@b170-jcnsd-3-2011-125],[@b171-jcnsd-3-2011-125]

Choosing Among Pharmacotherapy Options for Pediatric OCD and CTDs
=================================================================

Clinical management of pediatric obsessive compulsive disorder
--------------------------------------------------------------

The main choices among pharmacotherapy options for pediatric OCD include SSRIs and clomipramine. While clomipramine has demonstrated modestly superior outcomes relative to SSRIs, its side effects (especially its cardiovascular effects) limit its frontline use. Thus, SSRIs are most often used as first-line agents, with clomipramine used only after unsuccessful SSRI trials.[@b87-jcnsd-3-2011-125],[@b88-jcnsd-3-2011-125][Table 1](#t1-jcnsd-3-2011-125){ref-type="table"} provides a visual comparison of medications with RCT evidence for pediatric OCD. Although pharmacotherapy has demonstrated modest efficacy in the treatment of pediatric OCD, CBT with exposure and response prevention (E/RP) has demonstrated strong efficacy in pediatric OCD treatment, with meta-analytic results suggesting greater efficacy than pharmacological monotherapy.[@b60-jcnsd-3-2011-125],[@b61-jcnsd-3-2011-125] Exposure with response prevention has a more favorable side effect profile than pharmacotherapy and directly addresses the behavioral nature of obsessions and compulsions; CBT alone is considered the first line therapy for mild and moderate cases while CBT with an SSRI is recommended for severe cases.[@b72-jcnsd-3-2011-125] Cognitive behavioral therapy has been perceived as credible and effective by parents of children seeking anxiety treatment,[@b172-jcnsd-3-2011-125] and there are some indications that parents may prefer psychotherapy to SSRI use.[@b173-jcnsd-3-2011-125] However, a subset of children/families may be unwilling to participate in CBT, adhere to CBT principles, or may have poor insight into their symptoms, and pharmacotherapy may be particularly indicated for these populations. Another innovative treatment for pediatric OCD which combines CBT and biological treatments involves the use of D-cycloserine (DCS), a partial NMDA agonist which is proposed to enhance CBT outcome through facilitating fear extinction. While this is a relatively new approach to combining biological and behavioral approaches to OCD, DCS augmentation of CBT has displayed efficacy relative to CBT augmentation with pill placebo in children with OCD as well as other adult anxiety disorders, including OCD.[@b38-jcnsd-3-2011-125],[@b40-jcnsd-3-2011-125],[@b174-jcnsd-3-2011-125]--[@b176-jcnsd-3-2011-125] Generally, obsessive-compulsive symptoms remain chronic without appropriate treatment,[@b177-jcnsd-3-2011-125],[@b178-jcnsd-3-2011-125] and thus an intervention is recommended (in contrast to the option of no treatment) which considers the functional impairment experienced in proportion to the risk of adverse effects of the selected treatment.

Clinical management of pediatric chronic tic disorders
------------------------------------------------------

The main choices among pharmacotherapy options for pediatric CTDs include neuroleptics, atypical antipsychotics, and alpha-2 agonists. While neuroleptics have the most robust evidence base with regard to efficacy for pediatric CTDs, they also have a significant side effect profile. Thus, atypical antipsychotics and alpha-2 agonists have emerged as first-line pharmacotherapy options for pediatric CTDs,[@b103-jcnsd-3-2011-125],[@b179-jcnsd-3-2011-125] with neuroleptics reserved for treatment refractory cases with marked impairment. Like with medications for pediatric OCD, it is important to balance side effects with efficacy and it is recommended to increase dosages conservatively. [Table 2](#t2-jcnsd-3-2011-125){ref-type="table"} provides a visual comparison of medications with RCT evidence for pediatric CTDs.

For youth with CTDs, tics generally run a waxing and waning course, with many youth experiencing remission of tics by age 18.[@b55-jcnsd-3-2011-125],[@b89-jcnsd-3-2011-125] The majority of remaining youth will continue to exhibit tics, albeit with reduced severity compared to those experienced in childhood and adolescence, and a minority will continue to experience sustained tic symptoms. Given these observations, the option of no treatment or behavioral therapy should be considered in the context of presenting severity versus the side effects of the medication employed, with particular consideration given to habit reversal training (HRT). The central components of HRT involve creating awareness of premonitory urges in context and then implementing incompatible competing behaviors, such as contracting the muscle opposite of the tic. For example, a child may learn to identify that he has an eye-blinking tic when sitting in class, become able to identify it each time it happens, and then invoke a response where he consciously uses his eye muscles to hold his eyes open when feeling such an urge. Habit reversal training was the central component of the multi-site RCT for the Comprehensive Intervention for Tics (CBIT), along with functional analysis and relaxation training. In this large (N = 126), multi-site RCT, the CBIT intervention displayed an effect size of 0.68 relative to the control arm, with a reduction in tic severity comparable to contemporary medicinal interventions.[@b58-jcnsd-3-2011-125] Additionally, at 6 month follow up 87% of treatment responders contacted experienced continued benefit from the CBIT intervention. However, most patients were on medications during the trial and a head to head comparison of therapy to medication, similar to the Pediatric OCD Treatment Study (POTS)[@b72-jcnsd-3-2011-125] is needed. While CBIT is a promising intervention, it may not be appropriate for younger children and those with limited insight/motivation, and outcomes may be affected by certain comorbidities that would impact self-monitoring (eg, ADHD).

Clinical management of common comorbid conditions
-------------------------------------------------

Comorbid conditions in children present complexity in the context of therapeutic management for clinicians. Unfortunately, comorbidity is the rule rather than the exception in the clinical presentation of children with OCD and CTDs, and may be associated with attenuated response and remission rates.[@b180-jcnsd-3-2011-125]--[@b183-jcnsd-3-2011-125] It has also been observed that with CTDs, more impairment may be caused by the comorbid conditions than the tics themselves.[@b180-jcnsd-3-2011-125] In the context of pharmacotherapy, the presence of CTDs in children may substantially attenuate response to SSRIs for children with OCD, where one study found a 75% response rate for children with OCD only in comparison to a 53% rate for those children with OCD who also present with tics,[@b62-jcnsd-3-2011-125] and another found non-significance relative to placebo in post-hoc analyses for sertraline monotherapy in children with OCD and comorbid tics.[@b182-jcnsd-3-2011-125] Moreover, this comorbidity has been associated with a greater OCD relapse rate following paroxetine treatment.[@b62-jcnsd-3-2011-125] Further complicating matters is the fact that OCD is often comorbid with CTDs and depression,[@b82-jcnsd-3-2011-125]--[@b84-jcnsd-3-2011-125] and CTDs are frequently comorbid with OCD and ADHD.[@b184-jcnsd-3-2011-125] Given the high comorbidity rate found between OCD and CTDs (as well as with other conditions), clinicians often are faced with multiple decisions in treatment planning for these comorbid conditions. In general, the state of current psychopharmacological practice when presented with comorbidity for children with OCD and tics is to use the agent that is appropriate for each condition if pharmacotherapy is needed, while considering the possible negative or positive effects that the agent may have on comorbid conditions.[@b179-jcnsd-3-2011-125],[@b185-jcnsd-3-2011-125],[@b186-jcnsd-3-2011-125]

The situation is simplified in pharmacotherapy for OCD, where SSRIs can affect both OCD and depression/anxiety, and while they have not been observed to help with CTDs, they have not been associated with worsening of comorbid tics. On the other hand, with regard to comorbid ADHD and CTDs, while there is some evidence that stimulants may exacerbate tics and anxiety in children with CTDs,[@b187-jcnsd-3-2011-125],[@b188-jcnsd-3-2011-125] a meta-analysis by Bloch et al indicates that this effect may be dependent on the specific agent and dosing,[@b189-jcnsd-3-2011-125] and one multisite RCT found roughly equal tic increases when using methylphenidate, clonidine, or placebo.[@b190-jcnsd-3-2011-125] Although the issue of stimulants and CTDs presents with some contrasting evidence, using clonidine or guanfacine to address comorbid CTDs and ADHD simultaneously is a consideration when choosing among pharmacotherapy options for these conditions. Additionally, there is some evidence that risperidone and aripiprazole may have positive effects on anxiety symptoms,[@b185-jcnsd-3-2011-125],[@b186-jcnsd-3-2011-125],[@b191-jcnsd-3-2011-125] which is hypothesized to be a consequence of their action on 5HT receptors, and is a further consideration when treating comorbid CTDs and OCD.

Conclusion
==========

The goal of this review has been to discuss the current state of research on pharmacotherapy for pediatric OCD and CTDs, to provide an overview for clinical practice, and to demarcate current limitations in the literature to identify future research directions. While gains have been made in developing effective and safe/tolerable pharmacotherapy options for pediatric OCD and CTDs, much progress remains to be made. While pharmacotherapy is associated with generally positive treatment response, no current medication consistently achieves the more stringent criterion of symptom remission. Even with CBT for pediatric OCD (the most efficacious intervention reviewed), a significant proportion of children remain symptomatic following treatment.[@b72-jcnsd-3-2011-125],[@b192-jcnsd-3-2011-125] With regard to pediatric OCD, moving beyond the serotonin hypothesis into other domains such as ascertaining the role of glutamate may provide fertile ground for efficacy gains. For CTDs, identifying and evaluating safe and effective alternatives to neuroleptics and atypical antipsychotics are indicated, with the use of alpha-2 agonists and topiramate as a starting point. Across disorders, identifying moderators and mediators of response and side effects is of critical importance to facilitate treatment individualization. Identifying which populations respond better to a certain medicine or which patient groups are less likely to experience side effects from a particular agent could assist in improved idiographic care.

With regard to contemporary agents, more comparative work between medications in a randomized fashion could allow for direct comparisons of efficacy and adverse event rates. Many medications have demonstrated efficacy relative to placebo, and for a new medication to be of incremental value, it must be more efficacious or have better safety/tolerability than currently available agents, which is a hypothesis that may be best tested in a RCT with medications compared against one another. The evidence base is robust enough to move beyond the "nil hypothesis"[@b193-jcnsd-3-2011-125] that pharmacotherapy is better than no intervention at all, and to make further progress, the benchmark in many cases may be efficacious contemporary agents.

One further consideration is that that these medications are not prescribed in a vacuum, but are administered in the context of integrated behavioral healthcare. Careful weighing of the benefits and risks relative to the degree of impairment is of foremost importance when employing medications is needed, with particular regard given to available behavioral interventions. Moreover, given side effects of some agents, establishing a therapeutic relationship is of substantial consequence in promoting adherence to the intervention and comfort in reporting adverse events, and can also serve to empower a patient's decision making in treatment and provide a source of support to the patient in the face of functional interference. Such a relationship, often defined as the "therapeutic alliance", has been indicated for further exploration with pediatric psychopharmacology,[@b194-jcnsd-3-2011-125] and explains a portion of outcome variance in pharmacotherapy for adult depression as well as a variety of pediatric psychotherapies. It is also important to consider the family role with these conditions,[@b195-jcnsd-3-2011-125],[@b196-jcnsd-3-2011-125] with a particular focus on how the family may interact with the child's symptom presentation. For example, a family may overly accommodate a child's OCD symptoms or be overly critical of a child's CTD symptoms, which can serve to worsen symptoms. In the presence of heterogeneity among family reactions to the pathology, clinicians can foster a supportive but disciplined approach towards implementing the chosen intervention.

Compared to only 25 years ago, a marked increase in pharmacotherapy interventions have become available for children with OCD and CTDs to intervene for these debilitating conditions. This has provided an array of efficacious interventions for youth with markedly reduced side effect profiles, although much progress still remains to be made. Given this expansion of treatment options, the major decisions in clinical pharmacotherapy come down to a balance of efficacy and adverse effects in the context of functional impairment and available psychosocial interventions. Managing these variables in the context of the evidence base for each approach will foster improved child outcomes.
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###### 

Controlled evidence for pharmacotherapy options in the treatment of pediatric OCD.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medication class            Advantages                                                                                  Disadvantages                                                            Medication     Supporting research                                                                   Dose ranges employed   Duration of intervention   Outcomes[a](#tfn2-jcnsd-3-2011-125){ref-type="table-fn"}
  --------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ -------------- ------------------------------------------------------------------------------------- ---------------------- -------------------------- -------------------------------------------------------------------------------------
  Selective\                  Demonstrated efficacy compared to placebo and fewer side effects compared to clomipramine   Not as efficacious as clomipramine for pediatric OCD                     Fluoxetine     Liebowitz et al[@b64-jcnsd-3-2011-125]\                                               10--80 mg/day          8--16 weeks                49%--57% treatment response for medication, 25%--27% treatment response for placebo
  Serotonin\                                                                                                                                                                                                      Geller et al[@b18-jcnsd-3-2011-125]\                                                                                                    
  Reuptake\                                                                                                                                                                                                       Riddle et al[@b66-jcnsd-3-2011-125]                                                                                                     
  Inhibitors                                                                                                                                                                                                                                                                                                                                              

  Fluvoxamine                 Riddle et al[@b65-jcnsd-3-2011-125]                                                         50--200 mg                                                               10 weeks       42% treatment response formedication, 26% treatment response for placebo                                                                

  Paroxetine                  Geller et al[@b60-jcnsd-3-2011-125]\                                                        10--60 mg                                                                10--16 weeks   47%--71% treatment response formedication, 33%--41% treatment response for placebo                                                      
                              Geller et al[@b63-jcnsd-3-2011-125]                                                                                                                                                                                                                                                                                         

  Sertraline                  POTS[@b72-jcnsd-3-2011-125]\                                                                25--200 mg                                                               12 weeks       42%--53% treatment response for medication, 26%--37% treatment response for placebo                                                     
                              March et al[@b70-jcnsd-3-2011-125]                                                                                                                                                                                                                                                                                          

  Tricyclic Antidepressants   Most efficacious medication for pediatric OCD                                               Increased side effect profile, need for EKG and blood level monitoring   Clomipramine   DeVeaugh-Geiss et al[@b67-jcnsd-3-2011-125]\                                          50--200 mg             5--8 weeks                 58%--75% treatment response for medication, 10%--17% response for placebo
                                                                                                                                                                                                                  Flament et al[@b68-jcnsd-3-2011-125]\                                                                                                   
                                                                                                                                                                                                                  Leonard et al[@b17-jcnsd-3-2011-125]                                                                                                    
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Response rates calculated from multiple outcomes (eg, CY-BOCS,[@b197-jcnsd-3-2011-125] CGI-I[@b154-jcnsd-3-2011-125]).

###### 

Controlled evidence for pharmacotherapy options in the treatment of pediatric tic disorders.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medication class             Advantages                                                                                                                          Disadvantages                                                                                                              Medication        Supporting research                                                                                  Dose range employed                   Duration     Outcomes[a](#tfn4-jcnsd-3-2011-125){ref-type="table-fn"}
  ---------------------------- ----------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ----------------- ---------------------------------------------------------------------------------------------------- ------------------------------------- ------------ ----------------------------------------------------------------------------------------------------------------------------
  Neuroleptics                 Most robust evidence base in demonstrating efficacy for tics                                                                        Potential side effects include tardive dyskinesia and extrapyramidal symptoms                                              Pimozide          Sallee et al[@b106-jcnsd-3-2011-125]\                                                                0.5--4 mg                             4--8 weeks   Shown to reduce tic severity compared to placebo, mixed results when compared against risperidone
                                                                                                                                                                                                                                                                                                                Bruggeman et al[@b119-jcnsd-3-2011-125]\                                                                                                                
                                                                                                                                                                                                                                                                                                                Gilbert et al[@b113-jcnsd-3-2011-125]                                                                                                                   

  Atypical antipsychotics      Indicated to be as effective as neuroleptics, with little risk of tardive dyskinesia and extrapyramidal symptoms                    Side effect profile includes metabolic effects, sedation, and prolactin interference                                       Risperidone       Bruggeman et al[@b106-jcnsd-3-2011-125]\                                                             0.5--6 mg                             4--8 weeks   44%--63% treatment response for medication, 6%--26% treatment response for placebo
                                                                                                                                                                                                                                                                                                                Dion et al[@b120-jcnsd-3-2011-125]\                                                                                                                     
                                                                                                                                                                                                                                                                                                                Gaffney et al[@b118-jcnsd-3-2011-125]\                                                                                                                  
                                                                                                                                                                                                                                                                                                                Gilbert et al[@b113-jcnsd-3-2011-125]\                                                                                                                  
                                                                                                                                                                                                                                                                                                                Scahill et al[@b98-jcnsd-3-2011-125]                                                                                                                    

  Ziprasidone                  Sallee et al[@b100-jcnsd-3-2011-125]                                                                                                5--40 mg                                                                                                                   6 weeks           39% reduction in tic symptoms for medication, 16% symptom reduction for placebo                                                                         

  Alpha-2 Agonists             Demonstrated as efficacious compared to placebo, reduced side effect profile relative to neuroleptics and atypical antipsychotics   Reduced efficacy compared to neuroleptics and atypical antipsychotics                                                      Clonidine         Gaffney et al[@b118-jcnsd-3-2011-125]\                                                               0.1-.4 mg                             4--8 weeks   50%--69% treatment response for medication, 47% treatment response for placebo
                                                                                                                                                                                                                                                                                                                Du et al[@b138-jcnsd-3-2011-125]\                                                                                                                       
                                                                                                                                                                                                                                                                                                                Hedderick et al[@b101-jcnsd-3-2011-125]                                                                                                                 

  Guanfacine                   Scahill et al[@b102-jcnsd-3-2011-125]                                                                                               1.5--3 mg                                                                                                                  8 weeks           Significant reduction of tics compared to placebo                                                                                                       

  Anticonvulsants              Recently demonstrated efficacy at a level comparable to neuroleptics and atypical antipsychotics with fewer reported side effects   Less robust evidence base with regard to efficacy and side effects in pediatric tic disorders                              Topiramate        Jankovic et al[@b99-jcnsd-3-2011-125]                                                                25--200 mg                            10 weeks     Significant reduction of tics compared to placebo

  Baclofen                     Singer et al[@b155-jcnsd-3-2011-125]                                                                                                3 mg--60 mg                                                                                                                4 weeks           Significant improvement in overall impairment, but no significant reduction in motor or vocal tics                                                      

  Botulinum toxin              Avoids adverse events associated with continued medication administration                                                           Limited evidence for efficacy, does not address underlying psychopathology, tics may reassign to different parts of body   Botulinum toxin   Marras et al[@b159-jcnsd-3-2011-125]                                                                 Varied dose, but one only injection   2 weeks      39% reduction in number of tics observed for intervention group, 6% increase in number of tics observed for placebo groups

  Other dopamine antagonists   Preliminary indications of efficacy, provides alternatives to conventional pharmacological approaches                               Limited evidence base, undesirable side effect profiles, tiapride unavailable in the United States                         Tiapride          Eggers et al[@b165-jcnsd-3-2011-125]                                                                 5--6 mg/kg body wt                    10 weeks     Reduction of tics observed as assessed by behavioral evaluation in a RCT

  Metoclopromide               Nicolson et al[@b161-jcnsd-3-2011-125]                                                                                              5--40 mg                                                                                                                   8 weeks           64% treatment response for medication, 15% for placebo group                                                                                            
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Response rates calculated from multiple outcomes (eg, YGTSS,[@b156-jcnsd-3-2011-125] CGI-I[@b154-jcnsd-3-2011-125]).
